BRPI0805841A2 - agente para tratamento de esclerose múltipla - Google Patents

agente para tratamento de esclerose múltipla Download PDF

Info

Publication number
BRPI0805841A2
BRPI0805841A2 BRPI0805841-5A BRPI0805841A BRPI0805841A2 BR PI0805841 A2 BRPI0805841 A2 BR PI0805841A2 BR PI0805841 A BRPI0805841 A BR PI0805841A BR PI0805841 A2 BRPI0805841 A2 BR PI0805841A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment agent
agent
treatment
sclerosis treatment
Prior art date
Application number
BRPI0805841-5A
Other languages
English (en)
Inventor
Masaki Yamabi
Yuchiro Tabunoki
Toshiyuki Edano
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BRPI0805841A2 publication Critical patent/BRPI0805841A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AGENTE PARA TRATAMENTO DE ESCLEROSE MúLTIPLA. é descrito um agente oralmente administrável para prevenção e/ou tratamento de esclerose múltipla, que é altamente eficaz para esclerose múltipla e excelente na segurança. Especificamente descrito é um agente para prevenção e/ou tratamento de esclerose múltipla, que contém 2-benzil-5-(4-clorofenil)-6-[4-(metiltio)fenil]-2H-piridazin-3-ona ou um solvato do mesmo como um ativo ingrediente.
BRPI0805841-5A 2007-01-29 2008-01-28 agente para tratamento de esclerose múltipla BRPI0805841A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007017328 2007-01-29
PCT/JP2008/000099 WO2008093495A1 (ja) 2007-01-29 2008-01-28 多発性硬化症治療剤

Publications (1)

Publication Number Publication Date
BRPI0805841A2 true BRPI0805841A2 (pt) 2011-08-30

Family

ID=39673809

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0805841-5A BRPI0805841A2 (pt) 2007-01-29 2008-01-28 agente para tratamento de esclerose múltipla

Country Status (12)

Country Link
US (1) US20100075972A1 (pt)
EP (1) EP2127653A1 (pt)
JP (1) JPWO2008093495A1 (pt)
KR (1) KR20090114371A (pt)
CN (1) CN101600435A (pt)
AU (1) AU2008211480A1 (pt)
BR (1) BRPI0805841A2 (pt)
CA (1) CA2669563A1 (pt)
EA (1) EA200970720A1 (pt)
MX (1) MX2009008059A (pt)
TW (1) TW200838535A (pt)
WO (1) WO2008093495A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100626605B1 (ko) 1997-11-19 2006-09-22 코와 가부시키가이샤 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations

Also Published As

Publication number Publication date
JPWO2008093495A1 (ja) 2010-05-20
AU2008211480A1 (en) 2008-08-07
EA200970720A1 (ru) 2009-12-30
MX2009008059A (es) 2009-08-12
TW200838535A (en) 2008-10-01
CN101600435A (zh) 2009-12-09
US20100075972A1 (en) 2010-03-25
CA2669563A1 (en) 2008-08-07
EP2127653A1 (en) 2009-12-02
WO2008093495A1 (ja) 2008-08-07
KR20090114371A (ko) 2009-11-03

Similar Documents

Publication Publication Date Title
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
BR112015020650A2 (pt) inibidores de histona demetilases
CL2018001762A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas. (divisional solicitud 201402087).
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BR112015007083A2 (pt) inibidores de histona demetilases
SV2009002899A (es) Diarilureas para el tratamiento de la hipertension pulmonar
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
BR112015021352A2 (pt) composições antimicrobianas
TN2014000105A1 (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
NO20084749L (no) Organiske forbindelser og deres anvendelser
GEP201606580B (en) Topical compositions comprising fipronil and permethrin and methods of use
TW201625535A (en) Inhibitors of histone demethylases
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
CL2007002231A1 (es) Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
HK1203852A1 (zh) 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途
NO20083901L (no) Fiksert-dose-assosiasjon av fytat og sink
PH12020550673A1 (en) Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv)
HK1243951A1 (zh) 抗微生物组合和其在治疗微生物感染中的用途
BR112013005532A2 (pt) agente terapêutico para dor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE.